Chimeric HPV16 L1-L2 Capsid for Broad High-Risk HPV Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines are effective only against HPV16 and HPV18, requiring a cocktail of 15 different VLPs to induce antibodies against all high-risk HPVs, making them impractical for widespread use, and existing chimeric proteins show lower neutralizing activity against HPV31, HPV52, and HPV58.
Innovation Solution
A chimeric protein composed of HPV16 L1 protein with specific HPV16 L2 epitopes inserted in the loop region, specifically in the amino acid sequence 430 to 433, forming a capsid that induces cross-reactive neutralizing antibodies against multiple high-risk HPV types, including HPV16, 18, 31, 52, and 58, by incorporating 18-38, 56-75, or 96-115 L2 epitopes, and their variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a cocktail of 15 different VLPs is used to induce antibodies against all high-risk HPVs, then the coverage of HPV types is improved, but the device complexity and ease of manufacture deteriorate
Solution Approach 1:
The patent merges multiple HPV type specificities into a single chimeric protein by combining L1 protein from one HPV type with L2 epitopes from multiple high-risk HPV types. This single antigen can induce cross-reactive neutralizing antibodies against all 15 high-risk HPV types, eliminating the need for a complex cocktail of 15 different VLPs while maintaining broad coverage.
Solution Approach 2:
The chimeric L1/L2 protein serves multiple functions simultaneously: it acts as a structural capsid protein (L1 function) and presents multiple type-specific epitopes (L2 function) from different HPV types. This multi-functional design allows a single vaccine antigen to provide protection against multiple HPV types, achieving universality without requiring multiple separate vaccines.
2Adaptability or versatility
If existing chimeric proteins are used to induce cross-reactive antibodies, then the coverage of multiple HPV types is improved, but the neutralizing activity against certain HPV types (HPV31, HPV52, HPV58) deteriorates
Solution Approach 1:
The patent applies local quality by selectively incorporating specific L2 epitope regions (amino acid sequences 18-38, 56-75, and 96-115) into the chimeric protein structure. These specific local regions were identified as containing the critical neutralization epitopes that maintain high neutralizing activity across all HPV types including HPV31, HPV52, and HPV58, while the rest of the protein structure preserves the immunogenic L1 framework.
3Adaptability or versatility
If L2 protein with 60-75% amino acid homology is used as vaccine antigen, then the cross-reactivity to multiple high-risk HPVs is improved, but the binding efficiency deteriorates
Solution Approach 1:
The patent changes the parameters of the vaccine antigen by creating a chimeric protein that combines the high-immunogenicity L1 protein framework with specific L2 epitope sequences. This parameter change allows the antigen to achieve both high binding efficiency (from the L1 component) and broad cross-reactivity (from the L2 epitopes), resolving the trade-off between these two properties.
Data Source
AI summary
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is a particle formed by the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: LYKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-38 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).